Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea

Bausch Health

Status and phase: Enrolling; Phase 4

Conditions: Acute Diarrhea; Diarrhea; Bacterial Infection; Gastroenteritis

Treatments: Drug: Rifaximin 200 mg Tablet; Other: Oral Rehydration Therapy (ORT)

Study type: Interventional

Funder types: Industry

Identifiers

NCT07285785

RFPK1991

Details and patient eligibility

About

The goal of this clinical trial is to learn how rifaximin 200 mg is processed in the body (pharmacokinetics) in children 6 to 11 years old with acute diarrhea that may be caused by bacteria. It will also learn about the safety and effectiveness of rifaximin when given with oral rehydration therapy (ORT) compared with ORT alone. The main questions it aims to answer are:

How does rifaximin 200 mg move through and leave the body in children with acute diarrhea?

Is rifaximin safe for children in this age group?

Does rifaximin plus ORT help resolve diarrhea faster than ORT alone?

Researchers will compare rifaximin plus ORT to ORT alone to see if adding rifaximin improves outcomes.

Participants will:

Take one rifaximin 200 mg tablet + ORT three times a day for 3 days or receive ORT alone

Receive oral rehydration therapy according to the investigator's standard of care

Attend up to 4 clinic visits over 5 days and receive 4 follow-up phone calls

Provide blood samples on Day 1 and Day 3 for pharmacokinetic testing (rifaximin group only)

Provide stool samples to identify bacterial pathogens

Keep a diary of stool frequency and consistency to help determine when diarrhea resolves

Be monitored for side effects, vital signs, and laboratory changes

Full description

This is a randomized, open-label study to assess the pharmacokinetics of Xifaxan® 200 mg in pediatric participants 6 to 11 years of age with acute diarrhea of suspected bacterial etiology, and safety and efficacy Xifaxan® 200 mg plus ORT compared to ORT alone.

Participants will receive Xifaxan® 200mg (1 tablet) TID plus oral rehydration therapy (ORT) or ORT alone as per the Investigator's Standard of Care (SOC) for administering ORS for three days.

Participants will complete 3 or 4 study visits during the study; Screening (Day -2 to Day 1), Day 1, Day 3 (End of Treatment), and Day 5 (Last Clinic Visit), and 2 safety follow-up phone calls; Once during Day 6 to 8, and on Day 30 (End of Study). Participants may complete both Screening and Day 1 on the same day. At the Screening visit, participants will provide a stool sample for PCR testing to identify the bacterial pathogen isolated. During the 5-day study period, the participant or their caregiver will complete a diary to record the dose, the time of dosing, time and consistency of stools, and incidence of symptoms as defined above. In addition, the participant or the caregiver will record any AEs in the eDiary from Day 4 to Day 30 with Day 1 to Day 3 assessed during study visits.

Participants in the Xifaxan® 200 mg plus ORT arm will undergo two 6 to 8-hour pharmacokinetic sampling periods, the first following the first dose on Day 1 and the second following the first dose on Day 3. During these sampling periods, 3 blood samples (approximately 4 mL each) will be collected for analysis of rifaximin and 25- desacetyl rifaximin plasma concentrations at the following times: pre-dose, 1 hour (+/- 10 minutes) and no less than 6 but no more than 8 hours following the first dose of the day.

Enrollment: 54 estimated patients

Sex: All

Ages: 6 to 12 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

4.1 Inclusion Criteria

A participant will be eligible for inclusion in this study if all of the following criteria are met:

1. Parent/legally authorized representative and participant, as applicable, have provided written informed consent/assent, are able to understand, and agree to comply with, all study procedures and requirements.

2. Participant is between 6 to 11 years of age (inclusive)

3. Participant weighs at least 15 kg (33 lbs) at Screening

4. Participant is able to swallow pills

5. Participant has diarrhea of suspected bacterial etiology defined by:

   1. At least 3 unformed stools in the last 24 hours prior to Screening
   2. Illness for less than 96 hours at Screening
   3. Clinical presentation consistent with acute infectious diarrhea of suspected bacterial etiology

6. The participant agrees to use a highly effective method of contraception (if applicable) and to have urine pregnancy tests. Applies to females of childbearing potential (defined as postmenarche). Participants must practice at least 1 of the following medically acceptable methods of birth control throughout the study:

Applicable to:

All Post-Menarche Female Particpants:

• Highly effective hormonal contraception methods such as oral, implantable, injectable, vaginal ring, or transdermal contraception for a minimum of 1 full cycle (based on the participant's usual menstrual cycle period) before study drug administration.
• Total abstinence from sexual intercourse since the last menses before screening and agrees to total abstinence from screening until at least 30 days after last study drug administration.
• Intrauterine device.

All Males Participants:

• Condoms with spermicide.
• Total abstinence from sexual intercourse from screening visit until at least 30 days after last study drug administration.

4.2 Exclusion Criteria

A participant will not be eligible for inclusion in this study if any of the following criteria are met:

1. Participant has a history of chronic diarrhea (defined as loose or watery stools persisting for at last 4 consecutive weeks) within 12 months prior to onset of current acute illness.
2. Participant is unable to eat or drink.
3. Participant has clinical features suggestive of invasive or severe bacterial diarrhea requiring alternative therapy (e.g., frank blood in stool, mucoid diarrhea with systemic symptoms such as high fever, severe abdominal cramping or tenderness, or signs of sepsis).
4. Participant has taken >2 doses of anti-diarrheal therapies in the 24 hours prior to randomization.
5. Participant has taken any oral antimicrobial drug within 14 days of randomization.
6. Participant has a clinically significant or unstable medical condition, in the opinion of the Investigator, (including, but not limited to, evidence of severe dehydration noted by tachycardia, abnormal blood pressure, or decreased skin turgor) at the Screening visit.
7. Participant has a known hypersensitivity or allergy to Xifaxan®, rifampin, rifamycin-derived antibiotics, or any of the components of the rifaximin (Xifaxan®) formulations used in this study.
8. Participant is pregnant or lactating or plans to become pregnant during the study.
9. Participant has had a previous history of malignancy.
10. Participant has a history of tuberculosis infection and/or has received treatment for tuberculosis infection.
11. Participant has any concurrent illness, disability or circumstance that may affect the interpretation of clinical data, could cause noncompliance with treatment or visits or otherwise contraindicates participation in this study in the opinion of the Investigator.
12. Participant has had significant blood loss within the 30 days prior to the Screening visit which prevents the collection of the blood volume required for this study.
13. Participant has participated in an investigational drug or device study within the 30 days prior to randomization.
14. Participant is an immediate household family member of study site personnel directly involved in the conduct of this study.
15. Participant is taking a medication that is prohibited per Section 4.5 (Prohibited Therapy).

The following therapies are prohibited from Screening through Day 5:

• Anti-diarrheal medications, including:

  • Anti-motility agents (eg, loperamide, diphenoxylate, codeine, and paregoric).
  • Absorbent agents (eg, cholestryramine).
  • Anti-secretory agents (eg, bismuth subsalicylate, octreotide, and vapreotide).

• Probiotics

• Any antimicrobial agents with an expected activity against enteric bacterial pathogens

• A P-glycoprotein (P-gp) inhibitor

• Warfarin

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

54 participants in 2 patient groups

Rifaximin 200 mg + ORT

Experimental group

Description:

rifaximin 200 mg tablets orally three times daily for 3 days plus oral rehydration therapy (ORT) administered per investigator standard of care

Treatment:

Other: Oral Rehydration Therapy (ORT)

Drug: Rifaximin 200 mg Tablet

ORT Alone

Active Comparator group

Description:

ORT administered per investigator standard of care without rifaximin.

Treatment:

Other: Oral Rehydration Therapy (ORT)